Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2017 | The Scottish Cancer Prevention Network: an exemplary advocacy group

Annie Anderson • 5 Nov 2017
NCRI 2017
General

There is often a lack of communication about the strong evidence linking lifestyle to cancer risk. In this video, Annie Anderson, BSc, PhD, RD, FRCP from the University of Dundee, Dundee, UK, talks passionately about the Scottish Cancer Prevention Network (SCPN), an exemplary advocacy group. Prof. Anderson highlights the interesting and effective ways in which the SCPN disseminates lifestyle evidence on cancer risk reduction. This video was recorded at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK.

More from Annie Anderson

The importance of lifestyle intervention trials in cancer survivors
4:12
The importance of lifestyle intervention trials in cancer survivors
Annie Anderson • 5 Nov 2017
Designing effective lifestyle intervention trials
1:28
Designing effective lifestyle intervention trials
Annie Anderson • 5 Nov 2017
Changing society’s normative lifestyle behavior: the actions required to reduce cancer
7:06
Changing society’s normative lifestyle behavior: the actions required to reduce cancer
Annie Anderson • 5 Nov 2017
Recruiting for cancer research lifestyle programs
5:07
Recruiting for cancer research lifestyle programs
Annie Anderson • 5 Nov 2017

Related Videos

Radiotherapy before progression linked to lower TIL infiltration in patients with brain metastasis
3:14
Radiotherapy before progression linked to lower TIL infiltration in patients with brain metastasis
Ariane Steindl • 26 Oct 2026
Evaluating SL-28 allogeneic leukocyte therapy in advanced solid tumors
1:49
Evaluating SL-28 allogeneic leukocyte therapy in advanced solid tumors
George Tetz • 25 Oct 2026
HS-20122, an EGFR/cMET bispecific antibody-drug conjugate, in solid tumors
1:40
HS-20122, an EGFR/cMET bispecific antibody-drug conjugate, in solid tumors
Hongyun Zhao • 24 Oct 2026
Comparing the toxicity of HS-20122, a bispecific ADC, to other ADCs
1:02
Comparing the toxicity of HS-20122, a bispecific ADC, to other ADCs
Hongyun Zhao • 24 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals